{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-025532","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2022-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.833375+00:00","generated_at":"2026-06-21T14:49:30.077633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enanta reports Q4 net loss $26.3M, revenue $20.3M; initiates Phase 2 COVID-19 trial","bullets":["Q4 royalty revenue $20.3M (down 14% YoY); full year revenue $86.2M vs $97.1M.","Q4 net loss $26.3M ($1.27 loss per share) vs $24.6M loss ($1.22) prior year.","Cash $278.5M; expects runway into Q4 fiscal 2024.","Initiated Phase 2 SPRINT trial of oral 3CL protease inhibitor EDP-235 for mild/moderate COVID-19.","FY2023 guidance: R&D $210-230M, G&A $46-52M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-025532","json":"https://secwatch.observer/filing/0000950170-22-025532.json","markdown":"https://secwatch.observer/filing/0000950170-22-025532.md","text":"https://secwatch.observer/filing/0000950170-22-025532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017022025532/0000950170-22-025532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017022025532/enta-20221121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T14:49:30.077633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7db05da717aa482574c40feca18a0eedd8713461","claim":"ENANTA PHARMACEUTICALS INC reported twelve months ended September 30, 2022 results: revenue $86.2 million, net income Net loss was $121.8 million, EPS loss of $5.91 per diluted common share. Guidance initiated.","evidence_excerpt":"For the twelve months ended September 30, 2022, total revenue was $86.2 million compared to $97.1 million for the same period in 2021. Research and development expenses were $34.8 million for the three months ended September 30, 2022, compared to $48.9 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, research and development expenses were $164.5 million compared to $174.1 million in 2021. The decreases in both periods were due to the timing and scope of the company’s clinical trials. General and administrative expenses totaled $12.6 million for the three months ended September 30, 2022, compared to $8.4 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, general and administrative expenses were $45.5 million compared to $32.5 million in 2021. The increases in both periods were due primarily to additional headcount and stock compensation expense. Enanta recorded an income tax expense","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017022025532/0000950170-22-025532-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"twelve months ended September 30, 2022"},{"label":"Revenue","value":"$86.2 million"},{"label":"Net income","value":"Net loss was $121.8 million"},{"label":"EPS","value":"loss of $5.91 per diluted common share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fc89e5cad88c32974977a5c3d8106367377a93da","claim":"ENANTA PHARMACEUTICALS INC reported three months ended September 30, 2022 results: revenue $20.3 million, net income Net loss was $26.3 million, EPS loss of $1.27 per diluted common share. Guidance initiated.","evidence_excerpt":"Total revenue of $20.3 million for the three months ended September 30, 2022, consisted of royalty revenue derived from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET®, compared to royalty revenue of $23.6 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, total revenue was $86.2 million compared to $97.1 million for the same period in 2021. Research and development expenses were $34.8 million for the three months ended September 30, 2022, compared to $48.9 million for the three months ended September 30, 2021. For the twelve months ended September 30, 2022, research and development expenses were $164.5 million compared to $174.1 million in 2021. The decreases in both periods were due to the timing and scope of the company’s clinical trials. General and administrative expenses totaled $12.6 million for the three months ended September 30, 2022, compared to $8.4 million for the three months ended Septe","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017022025532/0000950170-22-025532-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Revenue","value":"$20.3 million"},{"label":"Net income","value":"Net loss was $26.3 million"},{"label":"EPS","value":"loss of $1.27 per diluted common share"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}